Table 2. IDO gene expression and enzymatic activity and neopterin concentration in patients and healthy controls.
| SMS | BT-AMS | DT-AMS | HC | |
|---|---|---|---|---|
| IDO (fold) | 1* # ¶ | 4.19 | 0.06 | 4.27 |
| (2.34–6.90) | (0.03–0.13)* ¶ | (0.75–6.57) | ||
| IFN-γ (fold) | 1* # ¶ | 0.02 | 0.005 | 0.03 |
| (0.01–0.03) | (0.003–0.13)* ¶ | (0.02–0.05) | ||
| Kyn (μM) | 2.48±0.51 # | 2.40±0.63 # | 1.85±0.35 | 2.65±.78 # |
| Trp (μM) | 78.80±14.11 | 73.69±11.63 | 76.89±10.77 | 69.21±16.40 |
| Kyn/Trp (mmol/mol) | 32.11±8.25 # | 34.52±11.78 # | 24.40±5.32* | 38.75±9.37 |
| Neopterin (μM) | 4.81±1.12 | 5.02±1.64 | 4.70±1.10 | 5.69±3.15 |
Data are expressed as mean ± standard deviation or as median and IQR percentile. SMS: multiple sclerosis patients in a stable phase of disease; BT-AMS: AMS patients before the initiation of glucorticoids; DT-AMS: AMS patients after the initiation of glucorticoids; HC: healthy controls. SE: standard error;
* p<0.05 compared to HC;
# p<0.05 compared to DT-AMS;
¶ p<0.05 compared to BT-AMS